

1 Outbreak risks, cases, and costs of vaccination strategies  
2 against wild poliomyelitis in polio-free settings: a modelling  
3 study

4  
5 Megan Auzenbergs<sup>1,2</sup>, Kaja Abbas<sup>1,2</sup>, Arie Voorman<sup>3,4</sup>, Corey Peak<sup>4</sup>, Mark Jit, Kathleen M O'Reilly<sup>1,2</sup>

6  
7 <sup>1</sup>Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK

8 <sup>2</sup>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK

9 <sup>3</sup>Institute for Disease Modelling, Seattle, WA, USA

10 <sup>4</sup>Bill and Melinda Gates Foundation, Seattle, WA, USA

11

12

13

14 Corresponding author:

15 Megan Auzenbergs

16 Megan.auzenbergs@lshtm.ac.uk

## 17 Abstract

### 18 Background

19 Polio eradication was threatened in 2022 by importation of wild poliovirus serotype 1 into Malawi  
20 with subsequent international spread, representing the first wild polio cases in Africa since 2014.  
21 Preventing importations and spread of wild poliovirus is critical, and dependent on population  
22 immunity provided through routine immunisation and supplementary immunisation activities (SIAs).  
23 However, the scale of preventative SIAs has reduced in recent years due to financial constraints.

### 25 Methods

26 We developed a mathematical model of polio transmission dynamics to evaluate the probability of  
27 an outbreak, expected number of poliomyelitis cases, and the costs associated with vaccination  
28 delivery through routine immunisation (RI), outbreak response SIAs (oSIAs) and preventative SIAs  
29 (pSIAs). Across varying levels of routine immunisation coverage, we explore three key strategies:  
30 RI+oSIAs, RI+oSIAs+annual pSIAs, and RI+oSIAs+biannual pSIAs.

### 32 Results

33 The annual pSIA strategy (RI+oSIAs+annual pSIAs) had higher costs but greater probability of no  
34 outbreaks: under our model assumptions, annual pSIAs result in 80% probability of no outbreaks  
35 when routine immunisation coverage  $\geq 50\%$ . The biannual pSIA strategy (RI+oSIAs+biannual pSIAs)  
36 costs less and averts more outbreaks than RI+oSIAs, but RI coverage  $\geq 65\%$  was required to achieve  
37 equivalent risk of no outbreaks. The strategy with no pSIAs (RI+oSIAs) had the lowest costs but  
38 required  $\geq 75\%$  RI coverage to achieve equivalent risk of no outbreaks.

### 40 Conclusion

41 Prioritisation of pSIAs must balance outbreak risk against implementation costs, ideally favouring the  
42 smallest manageable outbreak risk compatible with elimination. We infer that there are few short-  
43 term risks due to population immunity from RI, but without pSIAs, long-term risks accumulate and  
44 can result in outbreaks with potential for international spread. We do not consider the costs of  
45 further delaying the eradication timeline or societal implications of outbreaks, both of which  
46 emphasise the need for pSIAs.

## 47 Introduction

48 In 2019, the African Region was certified free from endogenous transmission of wild poliovirus  
49 (WPV), with the last case reported in Nigeria in July 2014 (1). However, in early 2022, Malawi and  
50 Mozambique reported WPV serotype 1 (WPV1) cases, linked to ongoing circulation in Pakistan (2, 3).  
51 The geographic distribution and genetic linkage of these WPV1 cases suggest missed transmission of  
52 an unknown geographic extent (2). These WPV1 cases highlight the importance of ensuring high and  
53 homogeneous levels of population immunity despite decreasing global incidence and elimination  
54 within the African continent (4). Historically, WPV1 outbreaks in Africa had a varied epidemiology—  
55 ranging in size from a few cases to explosive outbreaks that resulted in international spread and  
56 wide-scale outbreak responses. This variation can be attributed to population exposure to circulating  
57 virus and serotype-specific population immunity against poliovirus, among other factors (5).

58  
59 Since 2016, the recommended routine immunisation schedule is with bivalent oral polio vaccine  
60 (bOPV) and at least 1 dose of the inactivated polio vaccine (IPV) to provide population immunity.  
61 However, variable routine immunisation coverage leads to differential population immunity in  
62 different countries. The joint assessment of immunization coverage by UNICEF and WHO (WUENIC)  
63 estimated in 2021 routine vaccine coverage in Malawi and Mozambique was 93% and 61%,  
64 respectively. Also, low levels of population immunity persist in other areas, such as Liberia, where a  
65 recent study demonstrated poliovirus antibody seroprevalence was only 60% against serotype 1 (6).  
66 Further, the number of circulating vaccine derived poliovirus serotype 1 (cVDPV1) outbreaks has  
67 increased since 2022, suggesting that population immunity against this serotype has declined in  
68 some areas despite a rise in IPV coverage (which is expected to reduce the incidence of paralysis but  
69 has limited impact on transmission) (7).

70  
71 The Global Polio Eradication Initiative (GPEI) is responsible for the coordination of activities to  
72 support polio eradication. The activities include surveillance for acute flaccid paralysis (AFP) caused  
73 by polio infection, environmental surveillance (ES) for poliovirus, and providing polio vaccinations  
74 through both supplementary immunisation activities (SIAs) and routine immunisation (through the  
75 Expanded Programme for Immunisation (EPI)). The SIAs aim to vaccinate hard-to-reach children  
76 otherwise missed by RI (8). Despite an annual expenditure of hundreds of millions of USD, decision  
77 makers within polio eradication often must make difficult decisions in resource allocation. The global  
78 budget has remained relatively stable over the last decade with noted decreases in the last three  
79 years. Alongside, the frequency of preventative supplementary immunisation activities (pSIAs),  
80 which aim to strengthen population immunity and prevent the frequency and impact of outbreaks  
81 has decreased in almost all countries in Africa since 2017 (Figure 1) (9). However, the annual costs  
82 for vaccination and programmatic activities such as antiviral development and vaccine stockpiling  
83 carried out by GPEI have increased considerably (10, 11).

84  
85 *Figure 1. Historical pSIAs and RI coverage for 30 African countries (A) Average*  
86 *number of pSIAs per year from 2013-2017 and 2018-2022 and (B) year of last*  
87 *pSIA and WUENIC estimates of DTP3 coverage. Preventative SIAs were defined as*  
88 *either a national or subnational immunisation day (NID, SNID) with bOPV (or*  
89 *tOPV pre-2016) and did not occur within 365 days of a WPV1 or VDPV1 detection,*  
90 *to distinguish historic pSIAs from oSIAs. Any SIAs that occurred within 365 days of*  
91 *a WPV1 or VDPV1 outbreak were not included in the pSIA count. CAR= Central*  
92 *African Republic; DRC = Democratic Republic of the Congo*

93  
94 Since the World Health Assembly's 1988 resolution to eradicate polio by the year 2000, economic  
95 analyses have informed strategies to progress towards this goal. These studies inferred that polio  
96 eradication is cost-effective, assuming all vaccination stops following certification of global

97 eradication (12-14). Together, polio vaccination and achieving global polio eradication are estimated  
98 to save approximately 40 million DALYs by 2050 (15). However, existing economic analyses do not  
99 consider the cost-effectiveness of specific operational decisions for preventative SIAs (pSIAs) and  
100 outbreak response SIAs (oSIAs) given a shrinking budget (16) or are outdated and apply to limited  
101 geographies (17). The distinction between pSIAs and oSIAs is important because pSIAs and oSIAs  
102 have different strategic goals and funding approaches, and programmatic decisions between  
103 vaccination strategies are required imminently, not just in the future context of OPV cessation. We  
104 aim to compare strategies of differing frequency of pSIAs to that of RI and oSIAs to identify at what  
105 levels of RI the risks of outbreaks and polio cases may outweigh the associated costs of  
106 implementing pSIAs. This is an evidence gap identified by stakeholders that is important to address if  
107 and when we approach the final few years of WPV1 transmission and start to consider OPV  
108 cessation.  
109

## 110 Methods

111 The GPEI works with a fixed annual budget for their operations, based on donations from  
112 stakeholders. This budget is used to support the GPEI's objectives, including the global interruption  
113 of poliovirus transmission. Operationally, the planned budget is further divided into planned SIAs  
114 and outbreak response, and additional budget lines (not considered further in this study). Outbreak  
115 response includes oSIAs, and planned SIAs are either preventive in nature or used in endemic  
116 settings (not consider further here); pSIAs lower the risk of outbreaks due to the increase in  
117 population immunity. oSIAs include vaccination following a detected case (or at least two separate  
118 environmental detections that were collected from two different ES sites with no overlap in  
119 catchment area or collected from the same ES site at least two months apart (18)) and aim to raise  
120 population immunity in the affected areas to stop transmission. Operationally, pSIAs and oSIAs differ  
121 both in the target populations for vaccination as well as the funding and planning for activities –  
122 oSIAs must be implemented quickly and require more resource for rapid mobilisation. In this study,  
123 we consider only the risks of WPV1 outbreaks in a polio-free setting; the bOPV and IPV used in RI  
124 provide immunity against serotype 1. SIAs using bOPV also provide protection against infection as  
125 well as protection against paralysis. Outbreaks of vaccine-derived poliovirus serotype 2 require  
126 alternative vaccines and assumptions and are therefore beyond the scope of this analysis.  
127

128 We evaluated different pSIA vaccination strategies in addition to RI and oSIAs for a population of 8  
129 million children under five years of age, reflecting an average population size of a LMIC in Sub-  
130 Saharan Africa. We estimated costs alongside health benefits and risks for each vaccination strategy  
131 over a five-year time-period to align with the current GPEI timeline for polio eradication. Model  
132 outputs from each strategy include: probability of an outbreak, estimated cases of paralytic  
133 poliomyelitis and VAPP, number of outbreaks and estimated disability adjusted life years (DALYs)  
134 associated with these cases (Figure 2).  
135

136 *Figure 2. Health benefits, risks, and costs of polio vaccination. Schematic*  
137 *showing the relationships between vaccination, population immunity, paralytic*  
138 *poliomyelitis cases, adverse events and subsequent costs.*

139

## 140 Vaccination strategies

141 We explored three vaccination strategies (Table 1). We assume that vaccination via RI occurs in all  
142 strategies and follows a sequential immunisation schedule that includes 3 doses of bOPV given orally  
143 via drops in the mouth and 1 dose IPV administered intramuscularly or subcutaneously. The first two  
144 comparator strategies (RI+oSIAs+annual pSIAs and RI+oSIAs+biannual pSIAs) maintain the same

145 assumptions about baseline RI coverage, but additionally include one pSIA either every year or every  
146 two years, respectively, across time.

147

148 **Table 1. Polio vaccination strategies.** RI = Routine Immunisation, oSIA = outbreak response  
149 supplementary immunisation activity, pSIA = preventative supplementary immunisation activity. An  
150 outbreak response was only conducted if a simulation had at least 1 case of paralytic polio.

Vaccination strategy	Specification
Baseline strategy	RI + oSIAs *No preventative SIAs*
Comparator strategy 1	RI + oSIAs + <i>annual</i> pSIAs
Comparator strategy 2	RI + oSIAs + <i>biannual</i> pSIAs

151

152 In all strategies, we define an outbreak as at least one case of paralytic polio (18). An oSIA is  
153 conducted in all simulations for each strategy where at least one case was detected within any 90-  
154 day interval, in line with the median interval from notification to response as per the standard  
155 operating procedures (SOP) for polio outbreaks (18, 19). oSIAs continue until all cases are stopped  
156 over the five-year time horizon. We do not account for ES detections in this analysis. Children who  
157 were not vaccinated via RI, can receive additional doses of bOPV vaccine through either pSIAs or  
158 oSIAs. We assume that all SIAs reach 25% of children missed by RI, as prior evidence suggests that  
159 SIA coverage can be variable across locations and preliminary analysis of higher coverage for zero-  
160 dose children resulted in unrealistically high population immunity when compared to empirical data  
161 (20, 21). Appendix Table 4 includes a sensitivity analysis of different SIA assumptions.

162

## 163 Model structure

164 We developed a stochastic non-linear mathematical model to simulate polio transmission dynamics,  
165 whereby infectious individuals develop either asymptomatic or symptomatic infection, both of  
166 which are assumed to be infectious. We specify vaccine induced immunity based on OPV and IPV  
167 doses (Appendix Figure 1). In the model, children under five years of age are either susceptible, fully  
168 vaccinated and protected from poliovirus infection, or have received an incomplete vaccination  
169 series (less than 3 bOPV doses + 1 IPV dose). Each subsequent dose of vaccine corresponds to  
170 additional protection and an opportunity for a child to seroconvert and be considered fully  
171 protected from poliovirus infection. Further explanation of model compartments and transitions is in  
172 Appendix Table 1.

173

## 174 Time horizon and model assumptions

175 The modelled time horizon is five years, in line with the current GPEI strategic plan (22). The WPV1  
176 case to infection ratio was assumed to be 1:200, which is consistent with estimates for poliovirus  
177 serotype 1 (23). For polio, the basic reproductive number,  $R_0$ , can vary substantially between  
178 locations depending on sanitation and hygiene conditions (24). Here we have used an  $R_0$  of 3 for the  
179 primary analysis, supported by recent work exploring the parameter space of variable  $R_0$  values in a  
180 non-endemic setting in Africa for children under five years of age (20, 25), and explore other  $R_0$   
181 assumptions in a sensitivity analysis (Appendix Table 5). The proportion of children receiving three  
182 bOPV doses through RI at 6, 10, and 14 weeks is varied between 25%-100%, and for simplicity is  
183 assumed to occur upon entering the model. Children who have not seroconverted following  
184 vaccination or did not receive three or more doses of bOPV remain susceptible to infection. The  
185 proportion of children vaccinated with one dose of IPV is assumed to be equal to the third dose of  
186 bOPV RI coverage, which is in line with WUENIC data (26) (Appendix Figure 2). As of 2020, WHO  
187 recommends an additional IPV dose as part of RI (27), however, the number of countries that have  
188 introduced IPV2 as of 2023 are limited, therefore, we only consider IPV1 in our model.

189

190 We assume a fully mixed population of children under five years of age with no heterogeneity in the  
191 probability of a child being vaccinated in an SIA or in transmission of poliovirus. Simulations are run  
192 for 50 years before virus introduction, then one infection was introduced into the population at the  
193 start of the simulation and further importations were assumed to occur randomly at a rate of two  
194 importations per year. Different importation rates are reported in a sensitivity analysis in Appendix  
195 Table 6. The model was repeated for 1,000 stochastic simulations and run for five years. All models  
196 were run using the R package SimInf (28).

197

### 198 **Probability of an outbreak occurring**

199 For each vaccination strategy, the probability of an outbreak was calculated using the proportion of  
200 stochastic simulations that resulted in at least one case of paralytic polio (i.e., a polio AFP case) over  
201 the entire modelled time horizon. The probability of an outbreak is comparable to maintaining  
202 elimination in an infection-free setting such as most African countries. This definition is not directly  
203 comparable towards the WHO criteria for elimination status (29), but is useful for understanding  
204 outbreak risk. We do not include the specific criteria for elimination status as modelling of the  
205 processes that lead towards achieving eradication are beyond the scope of this analysis.

206

### 207 **DALYs**

208 DALYs were calculated for each strategy assuming that in LMICs, the average discounted lifetime  
209 DALYs associated with one paralytic poliomyelitis case, with no age-weighting is 14 DALYs per  
210 paralytic case of polio (30), assuming that one in 200 infections leads to irreversible paralysis and  
211 among those paralysed, 5-10% die when respiratory muscles become paralysed (31) and long-term  
212 mortality is approximately 20% higher in paralytic polio cases than the general population (32). The  
213 proportional contribution of YLD (years lost to disability) and YLL (years of life lost due to premature  
214 mortality) assuming 14 DALYs on average per case is 60% YLDs on average per case in addition to  
215 40% YLLs on average per case (33). We assume no international transmission during outbreaks for  
216 calculations of DALYs.

217

### 218 **Health and economic outcomes**

219 Incremental costs and incremental outcomes (in terms of DALYs and outbreaks averted) were  
220 estimated under each pSIA vaccination strategy in comparison to the baseline comparator  
221 (RI+oSIA). We used a 3% discount rate for costs and 0% for health with no age-weighting, with  
222 other discounting assumptions explored in Appendix Figure 5. The total cost for each comparator  
223 strategy included baseline RI vaccine costs for both bOPV and IPV. We present both a health system  
224 (excludes GPEI costs), and GPEI perspective (includes only GPEI costs) for specification of costs, but  
225 do not include indirect costs of vaccination, such as opportunity costs of time spent for vaccination.

226

### 227 **Vaccine costs**

228 Vaccine costs per dose for bOPV and IPV in Gavi supported countries were obtained from the latest  
229 UNICEF update in USD 2023, costing on average \$0.18 and \$2.00, respectively (34, 35) and  
230 administrative costs associated with polio RI were obtained from costs used in previous research  
231 (36), Appendix Table 3. All costs have been adjusted to 2023 USD. GPEI estimates OPV wastage  
232 ranges from 5-15% in SIAs and wastage is lower in SIAs than in RI (37). Estimates of IPV wastage vary  
233 between 5-20% in the literature (38) and country-specific analyses from Nigeria and The Gambia  
234 suggest IPV wastage can even be higher in practice, exceeding 20% for IPV wastage in some  
235 instances (39, 40). Accordingly, the main analysis assumes an average of 10% wastage for OPV in  
236 SIAs, 15% for OPV in RI and 15% for IPV, but further wastage assumptions are explored in a  
237 sensitivity analysis (Appendix Figure 6).

238

## 239 Data and analysis on SIAs in Africa

240 The Polio Information System (POLIS) (41) was used to obtain SIA data for 2013-2022 and further  
241 analysis was done to distinguish preventative campaigns from outbreak response campaigns. We  
242 assumed that pSIAs included National or Subnational Immunisation Days (NID, SNID) with bOPV (or  
243 trivalent OPV (tOPV) pre-2016) that did not occur within 365 days of a WPV1 or VDPV1 detection by  
244 AFP surveillance or ES. Any SIA that occurred within this interval was not included in the overall  
245 count of pSIAs. Country level historic pSIA number and year of last pSIA were presented alongside  
246 WUENIC estimates of Diphtheria Tetanus Toxoid and Pertussis vaccine third dose (DTP3) coverage  
247 (42), an indicator of vaccination via RI as the DTP vaccine is administered concurrently with OPV in  
248 the routine immunisation series.

249

## 250 SIA costs

251 The cost per child for both pSIAs and oSIAs was obtained from GPEI data (Appendix Table 7), for  
252 which an average across countries within the African Regional Office (AFRO) was used. Historic cost  
253 data for oSIAs has been less readily available, therefore, we assume oSIAs cost 2.0 times the cost of  
254 a pSIA, as per GPEI estimated costs for 2023. We also explore a range of proportional costs between  
255 pSIAs and oSIAs that align with previous assumptions in polio economic modelling (40) (Appendix  
256 Figures 7 and 8). Due to the stochasticity of epidemic simulations, there is considerable variability in  
257 outcomes for identical assumptions. The number of outbreaks, which affects total estimated costs, is  
258 variable and contributes to the variability in expected costs across all strategies (Appendix Figure 3).

259

## 260 Adverse events

261 The expected risk of adverse events, such as vaccine associated paralytic polio (VAPP) in countries  
262 using OPV is 1 case of VAPP per 0.9 million doses of bOPV administered and declines with  
263 subsequent doses (43). VAPP rate across settings with and without SIAs has been shown to vary (44),  
264 although this variation is not well understood or documented. OPV administration following IPV  
265 receipt is associated with a further risk reduction of VAPP (43) and is accounted for in model  
266 assumptions (Appendix Table 3). VAPP cases contribute to overall risk and costs for each strategy. A  
267 VAPP case was considered equivalent to a case of wild-acquired paralytic polio for calculation of the  
268 expected costs of VAPP.

269

## 270 Perspectives

271 Budget and incremental cost results are analysed from both the GPEI and health system  
272 perspectives. The GPEI costs include those associated with SIAs and IPV in RI. Treatment costs  
273 associated with paralytic polio (including VAPP) are paid for by the country and are included as  
274 health system costs. The probability of an outbreak under each vaccination strategy is analysed from  
275 both the global perspective for polio eradication and the country health system perspective.

276

## 277 Ethics

278 Ethical approval for this project was received from the London School of Hygiene and Tropical  
279 Medicine, project ID 15873.

## 280 Results

281 On average across all simulations, the expected number of WPV1 cases over five years is greatest in  
282 the baseline strategy (RI+oSIA) and least in the annual pSIA strategy (RI+oSIA+annual pSIA) (Figure  
283 3A). Under the base case assumptions (including  $R_0$  and proportion of zero dose children reached by  
284 SIA) annual pSIA achieve and maintain >80% probability of no outbreaks when baseline RI  
285 coverage is 50% (Figure 3B). The biannual pSIA strategy (RI+oSIA+biannual pSIA) achieves >80%  
286 probability of no outbreaks when RI is above 65% and the baseline strategy requires  $\geq 75\%$  RI  
287 coverage to achieve >80% probability of no outbreaks. The above results are from simulations  
288 assuming two importations per year during the five-year period of simulations. The frequency of  
289 importations was varied in a sensitivity analysis (Appendix Table 6); when RI was 50% or lower, the  
290 increased frequency of importation had a large increase on the probability of outbreaks, but for  
291 simulations with an RI  $\geq 75\%$ , the probability of no outbreaks remained above 80%.

292

293 *Figure 3. Estimated number of paralytic polio cases and probability that no*  
294 *outbreaks occur over the five-year modelled time horizon, (A) number of*  
295 *expected paralytic polio cases (presenting as a polio AFP case) and (B) probability*  
296 *of no outbreaks occurring across all vaccination strategies. Outbreak probability*  
297 *was based on 1,000 simulations per vaccination strategy. The red dashed line*  
298 *corresponds to 80% probability that no outbreaks occur.*

299

300 Expected VAPP cases over five years are greatest in the annual pSIA strategy, corresponding to the  
301 strategy with the greatest number of vaccine doses administered, but fewest expected WPV cases  
302 over five-years. Estimated costs from both the health system and the GPEI perspectives are shown in  
303 Figure 4. From a health system perspective, estimated costs are lowest in the annual pSIA strategy  
304 due to fewer polio cases. From the GPEI perspective, estimated costs of the annual pSIA strategy  
305 always exceed the cost of the baseline strategy due to the number of preventative campaigns.

306

307 *Figure 4. Health system and GPEI estimated total costs over five years. The size*  
308 *of the circle is proportional to the mean number of expected paralytic polio cases*  
309 *across all model simulations. The solid circles correspond to >80% probability the*  
310 *strategy had no outbreaks over a five-year period.*

311

312 Incremental costs per DALY averted by both pSIA strategies in comparison to the baseline strategy  
313 are shown in Figure 5 with further explanation of the quadrants in a cost-effectiveness plane  
314 (Appendix Figure 9). For non-GPEI costs (Figure 5A), when RI coverage exceeds 50%, points for both  
315 pSIA strategies are densely clustered in the bottom-right quadrant highlighting approaches with  
316 relatively lower costs and more DALYs averted. Assuming herd immunity is calculated by  $(1 - 1/R_0)$ ,  
317 when RI coverage exceeds 65%, the point when herd immunity is achieved in this simple  
318 homogeneously mixed model, the annual pSIA strategy becomes less efficient in averting DALYs. For  
319 GPEI costs (Figure 5B), which do not account for treatment or RI bOPV costs, at all levels of RI  
320 coverage, the annual pSIA strategy incurs relatively higher costs in comparison to biannual pSIA,  
321 with densely clustered points in top-right quadrant or along the positive y-axis. The cost  
322 effectiveness planes are presented in Appendix Figure 5 when a discount rate of 3% has been  
323 considered for both health and costs.

324

325 *Figure 5. Incremental costs per DALY averted. Incremental costs and DALYs*  
326 *averted under the annual pSIA (RI+oSIA+annual pSIA) and biannual pSIA*



327 *(RI+oSIA+biannual pSIAs) strategies are compared to the baseline strategy*  
328 *(RI+oSIA) assuming a 3% discount rate for costs and 0% discount rate for health.*  
329 *The points correspond to 1,000 model simulations. Here, it is assumed that the*  
330 *cost per child in an oSIA is two times the cost per child in a pSIA.*

331  
332 Incremental costs per outbreak averted capture the global perspective of polio eradication as a  
333 single outbreak under any vaccination strategy has implications for global polio eradication. This  
334 analysis has shown a greater number of outbreaks, albeit substantially smaller size, in the annual  
335 pSIA strategy in comparison to the baseline strategy when RI coverage is below 45% (under base-  
336 case assumptions), but the health system incremental costs are kept down by the small number of  
337 polio cases (Figure 6A). From the health system perspective, when RI coverage ranges from 45-70%,  
338 the annual pSIA strategy averts many outbreaks in comparison to the baseline strategy, but above  
339 70% RI coverage, the annual pSIA strategy does not avert many outbreaks and is a costly approach.  
340 Both pSIA strategies avert few to no outbreaks when RI coverage exceeds 75%. Under the GPEI  
341 perspective, the annual and biannual pSIA strategies avert a similar number of outbreaks above 60%  
342 RI coverage, but annual pSIAs have higher incremental costs per outbreak averted, corresponding to  
343 the greater number of SIAs conducted (Figure 6B).  
344

345 ***Figure 6. Incremental costs per outbreak averted.** Incremental costs and*  
346 *outbreak averted under the annual pSIA (RI+oSIA+annual pSIAs) and biannual*  
347 *pSIA (RI+oSIA+biannual pSIAs) strategies in comparison to the baseline strategy*  
348 *(RI+oSIA) assuming a 3% discount rate for costs and 0% discount rate for health.*  
349 *The points correspond to 1,000 model simulations. Here, it is assumed that the*  
350 *cost per child in an oSIA is two times the cost per child in a pSIA. An outbreak is*  
351 *defined as at least one case of paralytic polio. It is important to note that this*  
352 *figure does not suggest that the RI+oSIA strategy is better performing at low RI*  
353 *coverage levels. Instead, negative (or no) outbreaks averted by both pSIA*  
354 *strategies at low levels of RI coverage correspond to two phenomena: (i) the*  
355 *RI+oSIA strategy has larger explosive outbreaks when RI coverage is low, so the*  
356 *susceptible population is depleted quicker, whilst the pSIA strategies have much*  
357 *smaller, albeit more frequent, outbreaks when RI coverage is low.*

358  
359 The implications for decision making are outlined in Table 2. Focussing on estimated risk if historic  
360 pSIAs have been regularly conducted, when RI coverage falls below 40%, the annual pSIA strategy  
361 averts many cases, so removal of pSIAs entirely would create substantial risk. However, pSIAs do not  
362 avert many outbreaks. It is important to note that this finding does not suggest that oSIAs are  
363 necessarily better performing at these coverage levels. Instead, the baseline strategy instead leads  
364 to quicker depletion of susceptibles or, results in more frequent vaccination via outbreak response  
365 following *at least one* paralytic case, whereas the pSIA strategies only vaccinate the target  
366 population annually or biannually. Countries with 50-90% RI coverage and historic pSIAs have a  
367 higher probability of no outbreaks occurring, with the outbreak risk reducing with higher RI.  
368 However, the risk of an outbreak is not removed entirely until the probability of no outbreaks  
369 reaches 100% (when WPV1 transmission is interrupted globally). All strategies require >95%  
370 coverage for 100% probability that no outbreaks occur, however, above 80% RI coverage, outbreak  
371 probability is low and, if an outbreak does occur, the expected outbreak size is very small. Figure 1  
372 further summarises country-level historic pSIAs alongside the date since the last pSIA and current  
373 estimates of RI coverage. In summary, countries with <60% RI coverage have conducted more recent  
374 and frequent pSIAs and countries with >90% RI coverage have, on average, conducted fewer historic  
375 pSIAs per year. However, a few countries that fall below 80% RI coverage have not conducted a pSIA  
376 in over a decade.



378 **Table 2. Policy implications of polio vaccination strategies.** Implications for adopting each  
 379 vaccination strategy based on a country's RI coverage and historic SIA schedule according to GPEI SIA  
 380 data (column 2). Average values across all model simulations are references for DALYs averted and  
 381 outbreaks averted while expected paralytic polio cases are conditional averages amongst simulations  
 382 that resulted in at least one case. The probability of no outbreaks occurring is obtained from the  
 383 proportion of model simulations (out of 1,000 simulations) that resulted in zero paralytic cases and  
 384 correspond to important implications for polio eradication.

RI coverage	Did country conduct pSIAs in the past?	DALYs averted*?	Outbreaks averted*?	Estimated risk with annual pSIAs	Estimated risk with biannual pSIAs	Estimated risk relying on oSIAs only†	Implications for decision making
				Average number of polio cases if an outbreak occurs‡ (Probability <u>no</u> outbreaks occur)			
35%	L	L	X	5 (35%)	894 (3%)	15,753 (0%)	pSIA removal would have high risks and consequences
50%	L	L	L	1 (80%)	4 (33%)	3,549 (1%)	Removal of pSIAs altogether could lead to a high risk of outbreaks in subsequent years
55%	L	L	L	1 (89%)	2 (60%)	617 (3%)	
60%	L	L	L	1 (92%)	1 (76%)	34 (11%)	
65%	L	L	L	1 (94%)	1 (85%)	3 (37%)	
70%	L	X	L	1 (96%)	1 (91%)	1 (72%)	
80%	L	X	L	1 (97%)	1 (96%)	1 (92%)	Reducing the frequency of pSIAs could still maintain a low risk of large outbreaks
90%	L	X	L	1 (99%)	1 (99%)	1 (98%)	
100%	L	X	X	0 (100%)	0 (100%)	0 (100%)	Even if pSIAs are removed, there is low to no risk of outbreaks

385 \* Estimated DALYS and outbreaks averted are obtained from the annual pSIA strategy

386 † Estimated risk is obtained from the oSIA strategy assuming no pSIAs occur

387 ‡ Expected paralytic polio cases were calculated by taking the average number of paralytic polio cases across all stochastic model  
 388 simulations that had at least one case, so this is the average number of polio cases if an outbreak occurs

## 389 Discussion

390 The key messages of our study are: (i) with higher RI coverage of three doses of bOPV and 1 dose  
391 IPV, the probability of outbreaks reduces considerably – under our model assumptions, outbreak  
392 size and risk are minimal when RI is above 65%. At lower values of RI, specific vaccination strategies  
393 should be considered; (ii) in scenarios where RI is below 50%, annual pSIAs limit outbreak risk and  
394 result in high cost, an annual pSIA strategy when RI is 50-80% results in a low probability of  
395 outbreaks and continues to be costly, (iii) biannual pSIAs require higher baseline RI coverage (65%)  
396 to achieve an equivalent probability of no outbreaks, but the reduction in cost has few negative  
397 outcomes; (iv) a strategy with only RI and oSIAs implicitly accepts some level of outbreak risk, but if  
398 RI is above 70-80% the risk of outbreaks is considerably less than other settings where RI is below  
399 this value.

400  
401 At low levels (<50%) of RI coverage, the probability of outbreaks is high (99%) following an  
402 importation if pSIAs do not occur at any frequency. Further, the incremental costs show a clear  
403 benefit of a pSIA strategy, outweighing the increased number of expected VAPP cases and cost of  
404 vaccination. Countries such as Madagascar or South Sudan where 55% and 49% of the population  
405 under five years of age, respectively, are vaccinated with three or more DTP doses (used to  
406 approximate polio RI), have many subpopulations that could benefit from regular pSIAs. Indeed,  
407 between 2018-2022 South Sudan has implemented annual pSIAs, and Madagascar has implemented  
408 oSIAs in response to cVDPV1. Some countries in Africa have many subpopulations that fall towards  
409 the middle or upper range of analysed RI coverage estimates. In both Burkina Faso and Sierra Leone,  
410 for example, future SIAs would not seem necessary as routine immunisation coverage of three doses  
411 of bOPV and 1 dose IPV exceeds 90% without reliance on historic pSIAs, unless there are  
412 subpopulations with substantially lower coverage. The proportion of the population in Malawi that  
413 has received three doses of bOPV peaked in 2011, but has been unstable since, falling to 83% in  
414 2016 (26), with no historic reliance on pSIAs. WPV1 was reported in Malawi and local transmission  
415 and international spread has since been reported. In our analysis, RI exceeding 80% would be  
416 unlikely to result in an outbreak, but we have not included heterogeneity in immunity in the  
417 simulations, likely over-estimating the probability of no outbreaks. It may also be that the frequency  
418 of WPV1 importation was under-estimated for the Malawi setting, and close monitoring of migration  
419 routes from endemic countries remains an important component of preventing polio outbreaks.  
420 Whilst WHO now recommends two doses of IPV (IPV2) as part of RI, many countries in Africa have  
421 not yet implemented this strategy. As the number of countries adopting this policy decision  
422 increases, future studies will be needed to analyse the impact of IPV2.

423  
424 Our study has health policy implications for decision making on global polio eradication. Despite the  
425 high costs, the ability of pSIAs to decrease the probability of an outbreak is an important  
426 consideration for polio eradication. Should the GPEI adopt an annual pSIA strategy irrespective of  
427 estimated RI and importations? Annual pSIAs that include all children under five years of age in  
428 LMICs in Sub-Saharan Africa would consume most of the GPEI annual budget for activities and would  
429 be an inefficient use of funds, potentially reducing funds for other activities (surveillance,  
430 vaccination against other serotypes). However, prioritising SIAs in countries with low RI and  
431 perceived risk of introductions is a necessary compromise to which GPEI already adheres, and here  
432 we provide a framework to support decision making. When considering the vaccination strategies  
433 based on perceived outbreak risk (as described here) and the fixed budget for these activities, we  
434 must balance making the best use of limited resources while limiting WPV1 outbreak risk. The GPEI  
435 is reliant on a combination of country donations and philanthropic contributions to support  
436 activities, and budget has remained the same or reduced since 2010 and reduced further since the  
437 COVID-19 pandemic (45, 46). From the perspective of donors committing to polio eradication,  
438 reducing commitment prior to WPV1 interruption is a false saving: for every outbreak experienced,  
439 the timeline to WPV1 interruption become longer and the costs of eradication grows (22). Renewed

440 commitment by donors was requested in 2022 (47) in light of the 2022-2026 Strategic Plan and  
441 these commitments remain essential to resource the activities needed to meet the objectives of  
442 polio eradication, including interrupting WPV transmission.

443

444 Our study has limitations. The main results assume a  $R_0$  of 3 in a homogenous population (both with  
445 respect to transmission and population immunity), a frequency of poliovirus introduction of two  
446 infections per year and SIAs reaching 25% of children missed by routine vaccination. These  
447 assumptions are a necessary simplification of real-world complexity. Several assumptions for  $R_0$ ,  
448 poliovirus introductions, and SIA reach were considered in a univariate sensitivity analysis. Should  
449 SIAs reach up to 50% of zero-dose children, the impact of SIAs on reducing outbreak risk is further  
450 reduced, consequently for the same costs a better outcome is achieved. Assuming a higher  $R_0$  and  
451 increasing the frequency of importations would also increase the outbreak risk. One of the most  
452 uncertain inputs of the analysis is importation rate: as poliovirus infection is typically asymptomatic  
453 this is not directly observable (although ES has frequently illustrated introductions in the absence of  
454 AFP cases (48)), and due to the changing epidemiology of polio globally, the importation rate will  
455 vary in time. We have not considered heterogeneity in the population. If there are pockets of the  
456 target population with higher rates of transmission and/or lower vaccination coverage, then the  
457 probability of an outbreak occurring would be higher. Additional discussion on the model framework  
458 is presented in Appendix Section 1, page 5.

459

460 Further, the model structure assumes that children are vaccinated when they are born into the  
461 population, not accounting for infection prior to vaccination. Because the average age of infection  
462 with poliomyelitis occurs after the vaccination schedule of bOPV given at 6, 10 and 14 weeks of age  
463 alongside the effect of maternal antibodies, this limitation is unlikely to impact the expected number  
464 of AFP cases. However, because the size of the birth cohort vaccinated may be overestimated in the  
465 absence of infant mortality assumptions, the costs of RI may be over-estimated here. Additionally,  
466 we do not include indirect costs of vaccination, such as opportunity costs of time spent for  
467 vaccination, which may result in an underestimation of costs across all strategies. The indirect  
468 benefits of these additional interventions (such as productivity increases from averting polio cases)  
469 are also not quantified in the costs and benefits of SIAs described here, therefore the deaths and  
470 burden averted are polio specific and exclude indirect economic effects, in contrast to some other  
471 analyses. Since 2020, pSIAs have been reduced or stopped altogether across most LMICs in Sub-  
472 Saharan Africa, meaning 2023 represents the fourth consecutive year of diminished immunity. This  
473 analysis does not directly assess the consequences of this diminished immunity but presents  
474 baseline research that can be used to inform these future research questions. We do not consider  
475 the costs of further delaying the eradication timeline through outbreaks, or the societal implications  
476 of outbreaks on polio eradication, both of which may further emphasise the need to implement  
477 pSIAs even when the outbreak risks are small. By limiting our analysis to a five-year time horizon, we  
478 underestimate the benefits of SIAs (particularly pSIAs) as they will increase the likelihood of  
479 eradication, meaning that control efforts after eradication can be scaled back (though not stopped).  
480 Further, the pSIA health system costs only consider the geographical remit stated in the model and  
481 ignores the potential for further international spread. International spread would be far more likely  
482 with larger outbreaks, consequently the health system costs are under-estimated.

483

484 In settings that have not recently experienced a WPV1 outbreak, it is challenging to decide between  
485 responding to short-term versus long-term risks, especially with a fixed budget. From the global  
486 perspective striving to achieve polio eradication, investing in pSIAs results in a greater probability of  
487 polio elimination, but still require justification in a pragmatic environment of finite resources.  
488 Therefore, future funding provisions and advocacy for the importance of pSIAs rely on research that  
489 communicates risk and burden in their absence. Here, we communicate the utility of different  
490 vaccination strategies and critically assess the risks associated with adopting different strategies

491 given baseline RI coverage. Decisions made solely based on fixed budget, cost-effectiveness or  
492 burden reduction may not fully capture all consequences or benefits associated with adopting a  
493 particular vaccination strategy. Urgently, as importations of WPV remain a threat to the AFRO  
494 region, this analysis serves as an invaluable tool to estimate risk and plan vaccination activities  
495 across a range of settings.

496

#### 497 Authors' contributions

498 MA and KMOR conceptualised the study. MA curated the data, conducted the modelling analysis,  
499 prepared visualisations of results and wrote the original draft. MA, KMOR and KA independently  
500 validated the data and results. All authors contributed to reviewing results and editing of the  
501 manuscript and have approved the final version. The authors alone are responsible for the views  
502 expressed in this article and they do not necessarily present the decisions, policy or views of their  
503 affiliated organisations.

504

#### 505 Acknowledgements

506 This project was funded by the Bill and Melinda Gates Foundation (BMGF), OPP1191821. We would  
507 like to thank Rachel M. Burke (BMGF), Grace Macklin (WHO), John Edmunds (LSHTM), Anna Vassall  
508 (LSHTM), Stephan Widgren (SimInf), and others in the GPEI Subgroup for Analysis and Modelling for  
509 their time and feedback over the course of this project.

510

#### 511 Declaration of interests

512 The authors have no conflicts of interest to declare.

513

#### 514 Data sharing

515 Simulation code used in the analysis and sample model outputs can be accessed at:  
516 [https://github.com/mauzenbergs/polio\\_econ](https://github.com/mauzenbergs/polio_econ).

517

#### 518 Acronyms

519 Supplementary Immunisation Activities (SIAs), outbreak response SIAs (oSIA), planned preventative  
520 SIAs (pSIAs), Routine Immunisation (RI), Global Polio Eradication Initiative (GPEI), bOPV (bivalent oral  
521 polio vaccine), IPV (inactivated polio vaccine), circulating vaccine derived poliovirus (cVDPV), vaccine  
522 associated paralytic polio (VAPP), disability adjusted life years (DALYs), wild poliovirus serotype 1  
523 (WPV1), WHO (World Health Organization), The United Nations Children's Fund (UNICEF), WUENIC  
524 (WHO and UNICEF estimates of national immunization coverage), acute flaccid paralysis (AFP),  
525 environmental surveillance (ES), African Regional Office (AFRO), Bill and Melinda Gates Foundation  
526 (BMGF), low- or middle-income country (LMIC), London School of Hygiene and Tropical Medicine  
527 (LSHTM), standard operating procedures (SOP).

528

## 529 References


- 530 1. Etsano A, Gunnala R, Shuaib F, Damisa E, Mkanda P, Ticha JM, et al. Progress toward  
531 poliomyelitis eradication—Nigeria, January 2014–July 2015. *Morbidity and Mortality Weekly Report*.  
532 2015;64(32):878.
- 533 2. Malawi Ministry of Health, Global Polio Eradication Initiative, Davlantes E. Notes from the Field:  
534 Initial Outbreak Response Activity Following Wild Poliovirus Type 1 Detection—Malawi, February 2022.  
535 *Morbidity and Mortality Weekly Report*. 2022;71(23):776-7.
- 536 3. Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O'Leary A, et al. Progress Toward Polio Eradication  
537 - Worldwide, January 2020–April 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(19):650-5.
- 538 4. McCarthy K, Howard W, Yousif M, Moonsamy S, Suchard M. The show is not over—wild-type  
539 polio in Malawi is a wake up call and an opportunity for elimination efforts. *International Journal of*  
540 *Infectious Diseases*. 2022.
- 541 5. O'Reilly KM, Lamoureux C, Molodecky NA, Lyons H, Grassly NC, Tallis G. An assessment of the  
542 geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. *BMC Infect Dis*.  
543 2017;17(1):367.
- 544 6. Stephen B Kennedy GRM, Gloria Mason Ross. Poliovirus antibodies following two rounds of  
545 campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based  
546 seroprevalence survey. *Lancet Global Health*. 2023.
- 547 7. Franco-Paredes C, Rodriguez-Morales AJ, Henao-Martínez AF, Carrasco P, Tuells J. The growing  
548 threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era. *The Lancet Infectious Diseases*.  
549 2022;22(10):1412-4.
- 550 8. Global Polio Eradication Initiative. Polio endgame strategy 2019-2023: eradication, integration,  
551 certification and containment. World Health Organization; 2019.
- 552 9. Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, et al. Analysis of  
553 population immunity to poliovirus following cessation of trivalent oral polio vaccine. *Vaccine*. 2022.
- 554 10. Global Polio Eradication Initiative. GPEI Multi-year Budget 2019-2023: Enabling GPEI to  
555 Interrupt Poliovirus Transmission & Achieve Certification.
- 556 11. Thompson KM, Kalkowska DA. An updated economic analysis of the Global Polio Eradication  
557 Initiative. *Risk Analysis*. 2021;41(2):393-406.
- 558 12. Thompson KM, Tebbens RJD. Eradication versus control for poliomyelitis: an economic analysis.  
559 *The Lancet*. 2007;369(9570):1363-71.
- 560 13. Zimmermann M, Hagedorn B, Lyons H. Projection of Costs of Polio Eradication Compared to  
561 Permanent Control. *The Journal of Infectious Diseases*. 2019;221(4):561-5.
- 562 14. Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to  
563 support global polio eradication. *Expert Rev Vaccines*. 2020;19(7):661-86.
- 564 15. Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective.  
565 *Vaccine*. 2003;21(7):702-5.
- 566 16. Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance  
567 and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. *J*  
568 *Vaccines Vaccin*. 2016;7(5).
- 569 17. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling Strategies to Increase Population  
570 Immunity and Prevent Poliovirus Transmission in 2 High-Risk Areas in Northern India. *The Journal of*  
571 *Infectious Diseases*. 2014;210(suppl\_1):S398-S411.
- 572 18. Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus  
573 event or outbreak 2022 [Version 4: [Available from: [https://polioeradication.org/wp-](https://polioeradication.org/wp-content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliavirus-Event-Or-Outbreak-20220417_OBR_SOP_final_pre_pub_website.pdf)  
574 [content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliavirus-Event-Or-](https://polioeradication.org/wp-content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliavirus-Event-Or-Outbreak-20220417_OBR_SOP_final_pre_pub_website.pdf)  
575 [Outbreak-20220417\\_OBR\\_SOP\\_final\\_pre\\_pub\\_website.pdf](https://polioeradication.org/wp-content/uploads/2022/04/Standard-Operating-Procedures-For-Responding-to-a-Poliavirus-Event-Or-Outbreak-20220417_OBR_SOP_final_pre_pub_website.pdf).]
- 576 19. Blake IM, Chenoweth P, Okayasu H, Donnelly CA, Aylward RB, Grassly NC. Faster Detection of  
577 Poliomyelitis Outbreaks to Support Polio Eradication. *Emerg Infect Dis*. 2016;22(3):449-56.
- 578 20. Blake IM, Martin R, Goel A, Khetsuriani N, Everts J, Wolff C, et al. The role of older children and  
579 adults in wild poliovirus transmission. *Proceedings of the National Academy of Sciences*.  
580 2014;111(29):10604-9.

- 581 21. Voorman A, Lyons HM. Measuring polio immunity to plan immunization activities. *Vaccine*.  
582 2016;34(48):5946-52.
- 583 22. World Health Organization, Global Polio Eradication Initiative. Polio eradication strategy 2022–  
584 2026: delivering on a promise. 2021.
- 585 23. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis  
586 deconstructed. *American journal of epidemiology*. 2010;172(11):1213-29.
- 587 24. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Polio Vaccine Viruses:  
588 Implications for the Global Poliomyelitis Eradication Initiative. *American Journal of Epidemiology*.  
589 1999;150(10):1001-21.
- 590 25. McCarthy KA, Chabot-Couture G, Shuaib F. A spatial model of Wild Poliovirus Type 1 in Kano  
591 State, Nigeria: calibration and assessment of elimination probability. *BMC Infectious Diseases*.  
592 2016;16(1):521.
- 593 26. World Health Organization. Poliomyelitis vaccination coverage.
- 594 27. World Health Organization. *Weekly Epidemiological Record*, 2020, vol. 95, 22 [full issue].  
595 2020;95(22):241-56.
- 596 28. Widgren S, Bauer P, Eriksson R, Engblom S. SimInf: An R package for data-driven stochastic  
597 disease spread simulations. *arXiv preprint arXiv:160501421*. 2016.
- 598 29. Dowdle WR. The principles of disease elimination and eradication. *Bulletin of the World Health  
599 Organization*. 1998;76(Suppl 2):22.
- 600 30. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, et al. Economic  
601 analysis of the global polio eradication initiative. *Vaccine*. 2010;29(2):334-43.
- 602 31. World Health Organization. Poliomyelitis [Available from: [https://www.who.int/news-  
603 room/fact-sheets/detail/poliomyelitis](https://www.who.int/news-room/fact-sheets/detail/poliomyelitis)].
- 604 32. Nielsen NM, Rostgaard K, Juel K, Askgaard D, Aaby P. Long-term mortality after poliomyelitis.  
605 *Epidemiology*. 2003:355-60.
- 606 33. World Health Organization. The global burden of disease: 2004 update: World Health  
607 Organization; 2008.
- 608 34. UNICEF. Inactivated Polio Vaccine (IPV) price data [Available from:  
609 <https://www.unicef.org/supply/media/16266/file/IPV-vaccine-prices-14032023.pdf>].
- 610 35. UNICEF. oral polio vaccine price data 2022 [Available from:  
611 <https://www.unicef.org/supply/media/12671/file/oral-polio-vaccine-price-data-08062022.pdf>].
- 612 36. Kalkowska DA, Thompson KM. Health and economic outcomes associated with polio vaccine  
613 policy options: 2019–2029. *Risk Analysis*. 2021;41(2):364-75.
- 614 37. UNICEF. Guidance Note on Cold Chain Logistics and Vaccine Management During Polio  
615 Supplementary Immunization Activities. UNICEF, New York, NY; 2015.
- 616 38. Mvundura M, Hsu J-S, Frivold C, Kristensen D, Boyle S, Zehrung D, et al. Evaluating the cost per  
617 child vaccinated with full versus fractional-dose inactivated poliovirus vaccine. *Vaccine: X*. 2019;2:100032.
- 618 39. Wallace AS, Willis F, Nwaze E, Dieng B, Sipilanyambe N, Daniels D, et al. Vaccine wastage in  
619 Nigeria: An assessment of wastage rates and related vaccinator knowledge, attitudes and practices.  
620 *Vaccine*. 2017;35(48 Pt B):6751-8.
- 621 40. Thompson KM, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. *Risk  
622 Analysis*. 2021;41(2):349-63.
- 623 41. Global Polio Eradication Initiative. Polio Information System. 2023.
- 624 42. World Health Organization. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage.
- 625 43. Ni L, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes  
626 and epidemiology of poliomyelitis in the United States. *Jama*. 2004;292(14):1696-701.
- 627 44. Tebbens RJD, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. Risks of paralytic  
628 disease due to wild or vaccine-derived poliovirus after eradication. *Risk Analysis*. 2006;26(6):1471-505.
- 629 45. OECD. The 0.7% ODA/GNI target - a history [Available from:  
630 [https://www.oecd.org/dac/financing-sustainable-development/development-finance-  
631 standards/the07odagnitarget-ahistory.htm](https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/the07odagnitarget-ahistory.htm)].
- 632 46. Philip Loft PB. The 0.7% aid target. 2022.



- 633 47. Global Polio Eradication Initiative. GPEI calls for renewed commitments to achieve promise of a  
634 polio-free world 2022 [Available from: [https://polioeradication.org/news-post/global-polio-eradication-  
636 initiative-calls-for-renewed-commitments-to-achieve-promise-of-a-polio-free-world/](https://polioeradication.org/news-post/global-polio-eradication-<br/>635 initiative-calls-for-renewed-commitments-to-achieve-promise-of-a-polio-free-world/).  
637 48. Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S, El Bassioni L, et al. Environmental  
638 surveillance for polioviruses in the Global Polio Eradication Initiative. The Journal of infectious diseases.  
2014;210(suppl\_1):S294-S303.

A



B

Country	DTP3 coverage 2021	Year of last pSIA
RI coverage <50%		
CAR	42%	2021
Somalia	42%	2021
Guinea	47%	2021
South Sudan	49%	2021
>50% RI coverage <80%		
Madagascar	55%	2019
Nigeria	56%	2021
Chad	58%	2021
Mozambique	61%	2011
DRC	65%	2021
Ethiopia	65%	2021
Cameroon	69%	2021
Côte d'Ivoire	76%	2018
Benin	76%	2018
Mali	77%	2019
>80% RI coverage <90%		
Gambia	82%	2014
Niger	82%	2019
Togo	83%	2014
Sudan	84%	2019
Senegal	85%	2016
South Africa	86%	2010
Zimbabwe	86%	2007
>90% RI coverage		
Burkina Faso	91%	2016
Kenya	91%	2019
Uganda	91%	2019
Zambia	91%	2009
Sierra Leone	92%	2019
Malawi	93%	2010
Burundi	94%	2011
Botswana	95%	2004
Ghana	98%	2015


# Opportunities for vaccination



medRxiv preprint doi: <https://doi.org/10.1101/2023.07.05.23292288>; this version posted July 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).


## Vaccination increases population immunity

Increasing RI coverage or the frequency of SIAs increases the number of vaccine doses administered



A


Expected paralytic polio cases over 5 years



Vaccination strategy — RI + oSIAs — RI + oSIAs + annual pSIAs — RI + oSIAs + biannual pSIAs

B



Probability that no outbreaks occur











Vaccination strategy — RI + oSIAs — RI + oSIAs + annual pSIAs — RI + oSIAs + biannual pSIAs

# Total costs over 5 years

Size of the circles is proportion to the number of expected AFP cases  
 Solid points indicate >80% probability of no outbreak




Vaccination strategy  RI + oSIAs  RI + oSIAs + annual pSIAs  RI + oSIAs + biannual pSIAs

Number of AFP cases  0  5000  10000  15000  20000


A

## Health system perspective



B

## GPEI perspective




● RI + oSIAs + annual pSIAs ● RI + oSIAs + biannual pSIAs

Baseline comparator strategy is RI + oSIAs  
3% discounting for costs, 0% discounting for health

A


## Health system perspective



● RI + oSIAs + annual pSIAs ● RI + oSIAs + biannual pSIAs

B

## GPEI perspective



Baseline comparator strategy is RI + oSIAs  
3% discounting for costs, 0% discounting for health